肾素-血管紧张素系统抑制剂联合羟氯喹治疗IgA肾病的疗效及肾保护作用影响分析  

Analysis of the Efficacy and Impact of Renin-Angiotensin System Inhibitors Combined with Hydroxychloroquine in the Treatment of IgA Nephropathy and Nephroprotective Effects

作　　者：吴启美 徐兴欣[1] 卢文[1] WU Qimei;XU Xingxin;LU Wen(The First Affiliated Hospital of Anhui Medical University,Anhui Hefei 230000,China)

机构地区：[1]安徽医科大学第一附属医院肾内科,安徽合肥230000

出　　处：《河北医学》2023年第10期1740-1743,共4页Hebei Medicine

基　　金：安徽省重点研究与开发计划项目,(编号:202104a07020050)。

摘　　要：目的:探讨肾素-血管紧张素系统抑制剂(RASI)联合羟氯喹治疗IgA肾病的疗效及肾保护作用影响。方法:研究对象选择为2018年1月至2022年12月期间收治的IgA肾病患者共84例,采用简单随机分组法将研究对象分为对照组(42例)和观察组(42例),对照组患者服用RASI,观察组在对照组的基础上服用硫酸羟氯喹片,观察时间为3个月。比较两组患者的临床疗效。比较两组患者治疗前后肾功能指标及治疗安全性情况。结果:观察组治疗总有效率为92.86%,高于对照组76.19%(P<0.05);治疗后两组24-UPro水平低于治疗前(P<0.05),Scr水平高于治疗前(P<0.05),治疗后观察组血清24-UPro含量与治疗前的差值明显大于对照组(P<0.05),治疗后观察组血清Scr水平与治疗前的差值和UA水平与治疗前的差值比较差异无统计学意义(P>0.05);两组患者不良反应的发生率差异无统计学意义(P>0.05)。结论:肾素-血管紧张素系统抑制剂联合羟氯喹对于IgA肾病患者疗效较好,有助于控制蛋白尿、保护肾脏,维持肾功能稳定。Objective:To investigate the efficacy and renal protective effect of renin angiotensin system inhibitor(RASI)combined with hydroxychloroquine in the treatment of IgA nephropathy.Methods:The study subjects were 84 patients with IgA nephropathy admitted from January 2018 to December 2022.According to the random number table method,the study subjects were divided into the control group(42 cases)and the observation group(42 cases).The patients in the control group took RASI,and the observation group took hydroxychloroquine sulfate tablets on the basis of the control group for 3 months.The clinical effects of the two groups were compared.The renal function indicators and treatment safety of the two groups of patients before and after treatment were compared.Results:The difference in serum 24-UPro content between the observation group after treatment and before treatment was significantly greater than that of the control group(P<0.05).After treatment,the levels of 24-USPro in both groups were lower than before treatment(P<0.05),and the levels of Scr were higher than before treatment(P<0.05).There was no statistically significant difference in serum Scr level and UA level between the observation group after treatment and before treatment(P>0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion:The combination of renin-angiotensin system inhibitor and hydroxychloroquine has a good effect on patients with IgA nephropathy,helping to control proteinuria,protect the kidney and maintain the stability of renal function.

关 键 词：IGA肾病 肾素-血管紧张素系统抑制剂 羟氯喹 肾保护作用 

分 类 号：R692.31[医药卫生—泌尿科学]